Evidence map›Paper›PMID 39935485›Full record

ArticleFrontiers in immunology2025

Interleukin-1 signaling and CD4

Joseph M Gaballa, Caley Valdez, Douglas G Mack, Faiz Minhajuddin, Masoom Raza, Tabrez A Mohammad, Allison K Martin, Andrew Getahun, Charles A Dinarello, Andrew P Fontenot and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CCR1Journal of advanced research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joseph M Gaballa *Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Caley Valdez *Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Douglas G MackDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Faiz MinhajuddinDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Masoom RazaDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Tabrez A MohammadGreehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
Allison K MartinDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Andrew GetahunDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Charles A DinarelloDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Andrew P FontenotDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Shaikh M AtifDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Funding

Role of Chemokines in Innate and Adaptive Immunity in the LungR01HL152756 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ATIF, SHAIKH M · 2020 to 2023
$2.4M
Interactions between antigen-specific effector and regulatory T cells in beryllium-induced diseaseR01ES025534 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI FONTENOT, ANDREW P. · 2016 to 2020
$2.1M
Patient-Oriented Research in Immunologic Lung Disease.K24HL102245 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FONTENOT, ANDREW P. · 2010 to 2020
$1.4M
NHLBI NIH HHS K24 HL102245NHLBI NIH HHS R01 HL152756NIEHS NIH HHS R01 ES025534
6 · The paper itself

Abstract

Chronic beryllium disease (CBD) is a debilitating pulmonary disorder that occurs due to persistent exposure to beryllium (Be) particles in the workplace. Be-exposure causes activation of the innate immune system, resulting in the secretion of interleukins and chemokines that drive the accumulation of B and T cells in the lungs. However, the mechanisms by which innate molecules influence the recruitment of B cells and B cell-mediated protection in CBD are poorly understood. In this study, we employed multiple approaches to examine the role of innate immune signaling and CD4

Indexed as

BerylliosisB-LymphocytesCD4-Positive T-LymphocytesLungReceptors, Interleukin-1 Type ISignal TransductionAnimalsBerylliumChronic DiseaseDisease Models, AnimalImmunity, InnateMiceMice, Inbred C57BLMice, KnockoutReceptors, CXCR5BerylliumCXCR5 protein, mouseIL1R1 protein, mouseReceptors, CXCR5Receptors, Interleukin-1 Type IAnakinraberylliumchemokinesIL-1IL-1Rainflammationinterleukins

Identifiers

PMID39935485
PMCPMC11810750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.